×




Takeda Pharmaceutical Company (B): The Millennium Acquisition Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Takeda Pharmaceutical Company (B): The Millennium Acquisition case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Takeda Pharmaceutical Company (B): The Millennium Acquisition case study is a Harvard Business School (HBR) case study written by Charles O'Reilly, Asaka Itoh, Hiromichi Kimura, Chris D Beaumont. The Takeda Pharmaceutical Company (B): The Millennium Acquisition (referred as “Takeda Millennium” from here on) case study provides evaluation & decision scenario in field of Strategy & Execution. It also touches upon business topics such as - Value proposition, Emerging markets, Growth strategy, Mergers & acquisitions.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Takeda Pharmaceutical Company (B): The Millennium Acquisition Case Study


Yasuchika Hasegawa, president of Takeda Pharmaceutical Company, had a vision to make Takeda a top tier company in oncology by 2015. In 2008, Takeda acquired Millennium Pharmaceuticals, a respected oncology company with annual sales of $528 million in 2007 and a promising pipeline of new drugs. Hasegawa and Millennium CEO Deborah Dunsire believed that it was critical to convey a consistent vision for the future of Millennium within Takeda and help Millennium employees feel positive about the company's future. Millennium would operate independently and become Takeda's "Center of Excellence in Oncology." This case explores the steps that Hasegawa took to successfully integrate Millennium. His priorities centered on retaining Millennium talent and addressing the friction that arose from two very different corporate cultures. He also used the opportunity to transform Takeda's risk averse culture into a more innovative and flexible one that would support Takeda becoming a truly global pharmaceutical company.


Case Authors : Charles O'Reilly, Asaka Itoh, Hiromichi Kimura, Chris D Beaumont

Topic : Strategy & Execution

Related Areas : Emerging markets, Growth strategy, Mergers & acquisitions




Calculating Net Present Value (NPV) at 6% for Takeda Pharmaceutical Company (B): The Millennium Acquisition Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10008259) -10008259 - -
Year 1 3454554 -6553705 3454554 0.9434 3259013
Year 2 3955702 -2598003 7410256 0.89 3520561
Year 3 3946890 1348887 11357146 0.8396 3313885
Year 4 3241447 4590334 14598593 0.7921 2567530
TOTAL 14598593 12660988




The Net Present Value at 6% discount rate is 2652729

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Internal Rate of Return
2. Profitability Index
3. Net Present Value
4. Payback Period

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Takeda Millennium shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Takeda Millennium have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.






Formula and Steps to Calculate Net Present Value (NPV) of Takeda Pharmaceutical Company (B): The Millennium Acquisition

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Strategy & Execution Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Takeda Millennium often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Takeda Millennium needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10008259) -10008259 - -
Year 1 3454554 -6553705 3454554 0.8696 3003960
Year 2 3955702 -2598003 7410256 0.7561 2991079
Year 3 3946890 1348887 11357146 0.6575 2595144
Year 4 3241447 4590334 14598593 0.5718 1853308
TOTAL 10443491


The Net NPV after 4 years is 435232

(10443491 - 10008259 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10008259) -10008259 - -
Year 1 3454554 -6553705 3454554 0.8333 2878795
Year 2 3955702 -2598003 7410256 0.6944 2747015
Year 3 3946890 1348887 11357146 0.5787 2284080
Year 4 3241447 4590334 14598593 0.4823 1563198
TOTAL 9473088


The Net NPV after 4 years is -535171

At 20% discount rate the NPV is negative (9473088 - 10008259 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Takeda Millennium to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Takeda Millennium has a NPV value higher than Zero then finance managers at Takeda Millennium can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Takeda Millennium, then the stock price of the Takeda Millennium should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Takeda Millennium should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What will be a multi year spillover effect of various taxation regulations.

What can impact the cash flow of the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Understanding of risks involved in the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Takeda Pharmaceutical Company (B): The Millennium Acquisition

References & Further Readings

Charles O'Reilly, Asaka Itoh, Hiromichi Kimura, Chris D Beaumont (2018), "Takeda Pharmaceutical Company (B): The Millennium Acquisition Harvard Business Review Case Study. Published by HBR Publications.


REC SWOT Analysis / TOWS Matrix

Financial , Misc. Financial Services


Shutterfly SWOT Analysis / TOWS Matrix

Consumer Cyclical , Photography


4Cs SWOT Analysis / TOWS Matrix

Services , Retail (Catalog & Mail Order)


Minrav Projects SWOT Analysis / TOWS Matrix

Capital Goods , Construction Services


Meiwa Corp SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing


BRASKEM ON SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing